CCR7 and neoplasm: Moreover, naïve tumor-specific CD8+ T-cells, which seem less susceptible to anti-CCR7 therapy (244, 273, 274), can also become activated and gain effector-cell phenotypes directly at the tumor site, suggesting that cross-presenting DC are also able to prime CD8+ T-cells within the tumor (277).